Table 2 |
|||||
|
Adjusted register-derived process and clinical outcome data results for intervention and control groups. Odds ratios are estimates of the difference between intervention and control practices at follow-up, adjusting for differences at baseline and a systematic difference between registers. |
|||||
| Control Practices |
Intervention Practices |
||||
|
|
|||||
| Measures |
Baseline |
Follow-up |
Baseline |
Follow-up |
|
|
|
|||||
| Attendance |
Odds Ratio (95% CI) |
||||
| Proportion of patients with at least one appointment |
73.4% |
67.7% |
74.3% |
81.7% |
2.00* (1.02, 3.91) |
| Mean number of appointments |
1.23 |
1.35 |
1.29 |
2.02 |
Relative Risk 1.26 (0.87, 1.81) |
| Process of care |
|||||
| Fundoscopy recorded |
49.5% |
50.5% |
43.1% |
60.6% |
1.45 (0.88, 2.40) |
| Feet examination recorded |
46.1% |
48.8% |
48.0% |
67.3% |
1.87*(1.09, 3.21) |
| Dietary advice recorded |
19.9% |
29.2% |
25.3% |
46.3% |
2.77*(1.22, 6.29) |
| Smoking status recorded |
34.2% |
48.0% |
36.9% |
66.0% |
2.43*(1.18, 5.00) |
| Was subject a smoker? |
19.3% |
19.6% |
20.7% |
21.4% |
0.72 (0.38, 1.37) |
| BP recorded |
59.3% |
48.3% |
55.3% |
71.4% |
2.14*(1.06, 4.36) |
| HbA1c recorded |
64.0% |
66.0% |
60.9% |
79.0% |
1.58 (0.81, 3.08) |
| Cholesterol recorded |
57.0% |
61.1% |
53.3% |
78.0% |
1.66 (0.89, 3.12) |
| Creatinine recorded |
48.0% |
60.4% |
53.0% |
73.4% |
1.36 (0.72, 2.52) |
| Albumin:creatinine ratio recorded |
26.8% |
29.7% |
30.2% |
40.4% |
1.60(0.98, 2.60) |
| Clinical |
Difference |
||||
| Mean most recent systolic blood pressure |
144.5 |
144.6 |
145.8 |
144.2 |
-1.56 (-4.54, 1.42) |
| Mean most recent diastolic blood pressure |
80.2 |
78.1 |
79.2 |
77.8 |
-0.40 (-1.78, 0.97) |
| Mean most recent HbA1c# |
7.56 |
7.35 |
7.75 |
7.32 |
-0.04 (-0.18, 0.10) |
| Mean most recent cholesterol# |
5.27 |
5.06 |
5.23 |
4.94 |
-0.15**(-0.25, -0.06) |
| Mean most recent creatinine# |
93.1 |
96.1 |
91.8 |
95.7 |
0.21 (-1.27, 1.70) |
| Mean most recent albumin:creatinine ratio# |
8.99 |
8.45 |
8.48 |
8.05 |
-1.6 (-4.4, 1.2) |
| Diabetes medication |
Relative risk (95% CI) |
||||
| Biguanide, Sulphonylurea or Thiazol |
944 (49.0%) |
1128 (58.5%) |
646 (38.9%) |
923 (55.5%) |
1.06 (0.94, 1.19) |
| Metformin |
424 (22.0%) |
573 (29.7%)) |
343 (20.6% |
530 (31.9) |
1.07 (0.81, 1.41) |
| Insulin |
57 (3.0%) |
75 (3.9%) |
54 (3.2%) |
75 (4.5%) |
1.15 (0.83, 1.58) |
| Cardiovascular risk factor drugs |
|||||
| Aspirin |
10 (0.5%) |
164 (8.5%) |
34 (2.0%) |
308 (18.5%) |
2.08* (1.00, 4.32) |
| Ace Inhibitor |
17 (0.9%) |
103 (5.3%) |
31 (1.9%) |
185 (11.1%) |
2.03* (1.08, 3.78) |
| ACE inhibitor or Angiotensin-II receptor antagonist |
21 (1.1%) |
109 (5.7%) |
38 (2.3%) |
192 (11.6%) |
1.86* (1.03, 3.38) |
| Any antihypertensive |
118 (6.1%) |
274 (14.2%) |
131 (7.9%) |
415 (25.0%) |
1.89*(1.16, 3.08) |
| Lipid-lowering |
110 (5.7%) |
290 (15.0%) |
79 (4.8%) |
418 (25.2%) |
1.66 (0.99, 2.79) |
| Any medication |
1674 (86.9%) |
1838 (95.4%) |
1283 (77.2%) |
1549 (93.2%) |
1.01 (0.94, 1.08) |
|
|
|||||
|
*p < 0.05, **p < 0.01, *** p < 0.001 # Data downloaded into register database directly from hospital laboratory information system. |
|||||
|
Eccles et al. Implementation Science 2007 2:6 doi:10.1186/1748-5908-2-6 |
|||||
